TMG finishes annual survey of PACS, teleradiology sitesTechnology Marketing Group has released a PACS census that includes data on more than 1700 PACS and teleradiology sites in the U.S. TMG has learned that one-third of the survey respondents
Technology Marketing Group has released a PACS census that includes data on more than 1700 PACS and teleradiology sites in the U.S. TMG has learned that one-third of the survey respondents plan to purchase more PACS equipment, among other findings.
The survey also includes data on the U.S. market as a whole and on individual sites. Facility profiles include: installed PACS equipment by component; applications by location and function; and 1996-1998 equipment purchase plans with budget ranges. In compiling the census, TMG conducted interviews with key staff at hospitals of 200 beds or more in the U.S., as well as clinics, imaging centers, and other non-hospital settings.
The TMG survey was conducted in conjunction with professional societies such as the Society for Computer Applications in Radiology. Companies in the diagnostic imaging and PACS market provided funding for the survey, according to Des Plaines, IL-based TMG.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.